aTyr Pharma, Inc.

NASDAQ:ATYR

Biotechnology

Healthcare
$0.53 +14.23%

+$0.07 today

Market cap
$52.13M
Beta
0.54
P/E (TTM)
-0.7
EPS (TTM)
-$0.71
52W Low $0.40High $7.29

Volume 1.02M

Average 2.29M

Returns on capital

aTyr Pharma, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-109.8%

avg -75.0%

ROIC

-96.5%

avg -61.6%

ROA

-78.7%

avg -54.4%

Analysis

ROA is currently the strongest return metric at -78.7% versus its period average of -54.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Sanjay S. Shukla

President, Chief Executive Officer & DirectorUSD 861.05K54——

Jill Broadfoot

Chief Financial OfficerUSD 596.23K64——

Nancy E. Denyes Krueger

General Counsel & Corporate SecretaryUSD 571.16K58——

Leslie Nangle

Vice President of Research————

Ashlee Dunston

Director of Investor Relations & Corporate Communications————

Dalia R. Rayes

Head of Commercial, Global Efzofitimod Franchise————

Peter Villiger

Vice President of Corporate Development————

Danielle Campbell

Vice President of Human Resource————

Compensation is shown in the reported currency; data updated Aug 8, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

1

$49,630.00

Sells

3

$6,267.01

Net Transaction Value

+$43,362.99

Net buying

Most Active

SCHIMMEL PAUL

1 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
May 27, 26

SCHIMMEL PAUL

Indirect

Buy$49.6K
Feb 4, 26

DENYES NANCY

Direct

Sell$1.1K
Feb 4, 26

Broadfoot Jill Marie

Direct

Sell$1.5K
Feb 4, 26

Shukla Sanjay

Direct

Sell$3.7K

Summary

Insiders reported 1 buys worth $49,630.00 and 3 sells worth $6,267.01 over the last 12 months. That adds up to net buying of $43,362.99. SCHIMMEL PAUL was the most active insider with 1 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A4 analysts
RevenueN/AN/A-73.7%
+293.4% (5yr)5 analysts
Net IncomeN/AN/AN/A
N/A5 analysts
EBITN/AN/AN/A
N/A5 analysts

Analysis

Recent growth has been strongest in Revenue at -73.7% over three years. Forward estimates point to Revenue at +293.4% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does aTyr Pharma, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about ATYR's management, answered from reported figures.

Who manages ATYR?

aTyr Pharma, Inc. (ATYR) lists 8 active executives. The top listed executive is Leslie Nangle, Vice President of Research.

Are ATYR insiders buying or selling?

Recent insider activity shows net buying of $7.65M.